Phase II Study Evaluating Teniposide as Post-Line Therapy for c-Myc-Driven Extensive-Stage Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer (ES-SCLC) who have high expression of the c-Myc-driven FBXW2/MYC gene and have not responded to standard treatments. This phase II clinical study aims to explore how the expression of FBXW2/MYC correlates with the treatment effects of teniposide in this patient group. Participants will receive teniposide administered intravenously at a dose of 60 mg/m2, diluted in 500 ml of 0.9% sodium chloride, infused over more than one hour daily for 3 to 5 consecutive days. One treatment cycle lasts 21 days. Imaging evaluations will be performed at the start and then every 6 to 8 weeks during treatment, with an average study duration of one year. During the study, researchers will monitor the objective response rate through imaging, as well as disease control rate, progression-free survival, and duration of response. Safety monitoring includes tracking adverse and serious adverse events from baseline until 30 days after the last dose. Participants can expect regular assessments and imaging scans throughout their involvement, which may last about one year.

Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer